Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose hCG priming in diminished ovarian reserve undergoing IVF/ICSI
2025-521234-28-00Phase 3Authorised
- Sponsor
- Rigshospitalet
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of recombinant human chorionic gonadotrophin in female infertility and Diminished Ovarian Reserve (DOR) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Number of oocytes retrieved. Planned start Sep 2025; status: authorised.
02
Drugs
recombinant human chorionic gonadotrophin
03
Conditions
female infertilityDiminished Ovarian Reserve (DOR)
Beyond the preview
Go deeper on 2025-521234-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521234-28-00.